Related Experiment Video

Updated: Sep 18, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Hemogram-derived ratios as prognostic markers for major adverse cardiovascular events in patients with non-ST-segment

Emir Bećirović1, Minela Bećirović2, Sabina Šegalo3

  • 1Department of Intensive Care, University Clinical Center Tuzla, Tuzla 75000, Bosnia and Herzegovina.

World Journal of Methodology
|June 23, 2025
PubMed

Insights

Hematological-derived ratios, including neutrophil-to-lymphocyte ratio (NLR), predict major adverse cardiovascular events (MACE) in non-ST elevation myocardial infarction (NSTEMI) patients. NLR at T2 showed the highest diagnostic performance for lethal outcomes.

Area of Science:

  • Cardiology
  • Hematology
  • Clinical Medicine

Background:

  • Non-ST segment elevation myocardial infarction (NSTEMI) presents complex clinical management challenges due to varied patient outcomes.
  • Identifying prognostic markers is crucial for risk stratification and improving care for NSTEMI patients.

Purpose of the Study:

  • To assess the predictive capability of hemogram-derived ratios (HDRs) for major adverse cardiovascular events (MACE) in NSTEMI patients.
  • To enhance clinical outcomes through improved risk stratification using hematological parameters.

Main Methods:

  • A prospective, observational cohort study involving 170 NSTEMI patients was conducted.
  • Patients were categorized into groups with and without MACE, and further into lethal and non-lethal outcomes.
  • Thirteen hematological-derived ratios (HDRs) were analyzed alongside standard hematological parameters.

Main Results:

  • Standard hematological parameters showed no significant differences between MACE and control groups.
  • Significant disparities in HDRs were observed between lethal and non-lethal outcomes.
  • Neutrophil-to-lymphocyte ratio (NLR) at T2 demonstrated high diagnostic performance (AUC 0.811) for predicting lethal outcomes.

Conclusions:

  • Hemogram-derived indexes, particularly NLR, possess significant prognostic value for predicting MACE in NSTEMI patients.
  • NLR, PLR, and CRP/Ly provide valuable insights into inflammatory processes post-cardiovascular events.
Abstract

Keywords:
Hemogram-derived ratiosMyocardial infarctionNeutrophil-to-lymphocyte ratioPrognostic markers

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.3K
Histological Quantification of Chronic Myocardial Infarct in Rats09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

14.8K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
353
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
223
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
26
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
123
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
71
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
261